Table 2.
Summary of the ongoing trials evaluating ADC-based combinations in breast cancer
| Antibody drug conjugate | Payload | Combined drug | Population | Trial | Phase | Status |
|---|---|---|---|---|---|---|
| Mirvetuximab sorvatansine (IMGN853) | DM4 (tubulin inhibitor) | Gemcitabine | Basket trial including mTNBC | NCT02996825 | I | Active, not recruiting |
| Anetumab ravtansine | DM4 | Gemcitabine, Cisplatine | Basket trial including mTNBC | NCT03102320 | I | Completed |
| Ladiratuzumab vedotin (SGN-LIV1A) | MMAE (tubulin inhibitor) | Trastuzumab | Her2 + BC | NCT01969643 | I | Recruiting |
| Atezolizumab | mTNBC | NCT03424005 | I/II | Recruiting | ||
| ARX788 | ARX788 | Pyrotinib | Her2 + BC | NCT04983121 | I | Recruiting |
| Sacituzumab govitecan | SN-38 (topoisomerase 1 inhibitor) | Talazoparib | mTNBC | NCT04039230 | I/II | Recruiting |
| Alpelisib | HER2- BC | NCT05143229 | I | Recruiting | ||
| Atezolizumab | TNBC | NCT04434040 | II | Recruiting | ||
| Pembrolizumab | mTNBC | NCT05382286 | III | Recruiting | ||
| Pembrolizumab | TNBC | NCT04230109 | II | Active not recruiting | ||
| Trastuzumab emtansine | DM-1 | Abemaciclib | HER2 + BC | NCT04351230 | II | Withdrawn^ |
| Utomilimab | HER2 + BC | NCT03364348 | I | Completed* | ||
| Trastuzumab deruxtecan | Exatecan derivative (topoisomerase 1 inhibitor) | Pembrolizumab | Lung cancer and BC | NCT04042701 | I | Recruiting |
| Nivolumab | Urothelial cancer and BC | NCT03523572 | I | Active not recruiting | ||
| Tucatinib | HER2 + BC | NCT04539938 | II | Recruiting | ||
| HER2 + BC | NCT04538742 | I/II | Recruiting | |||
| Durvalumab | (module 1) | |||||
| Pertuzumab | (module 2) | |||||
| Paclitaxel | (module 3) | |||||
| Paclitaxel + durvalumab | (module 4) | |||||
| Tucatinib | (module 5, 6) | |||||
| HER2-low BC | NCT04556773 | I | Recruiting | |||
| Capecitabine | (module 1) | |||||
| Paclitaxel + durvalumab | (module 2) | |||||
| Capivasertib | (module 3) | |||||
| Anastrazole | (module 4) | |||||
| Fulvestrant | (module 5) | |||||
| Pertuzumab | HER2 + BC | NCT04784715 | Recruiting |
^There were no patients enrolled in this study
*Results not reported at the time of the review publication
BC: breast cancer; mTNBC: metastatic triple negative breast cancer; TNBC: triple negative breast cancer